IHE vs THNR

IHEBiShares U.S. Pharmaceuticals ETF

THNRCAmplify Weight Loss Drug & Treatment ETF

In short

IHE The domestic purist of pharma funds: about 60 US drug and vaccine makers, weighted by size, no foreign names riding along. Running since 2006, it is the plain cap-weighted take on Big Pharma.

THNR The GLP-1 trade in one ticker. THNR follows a global index of weight-loss drug developers plus the telehealth and treatment companies the index counts as economic beneficiaries, not just the obvious pharma giants.

Stated mandate

IHE The fund seeks to track an index of U.S. companies in the pharmaceuticals sector, giving investors targeted exposure to domestic drug manufacturers and vaccine producers.

THNR The fund provides access to global companies involved in weight-loss drug development or expected to benefit economically from increased use of these treatments, including drug manufacturers and telehealth providers.

Why people hold it

• IHE Costs 0.37% a year against a 0.57% median for pharma funds, landing within a basis point or two of the cheapest options in the group.
• Tracks the Dow Jones U.S. Select Pharmaceuticals Index: domestic drug and vaccine makers only, not the US-listed foreign pharma that PPH's index also picks up.vaneck.com
• Trading since 2006 under the iShares banner, now a billion-dollar-plus fund with moderate daily volume and quarterly distributions.
• Sits in the upper half of its pharma peer group on our review, one of the sturdier implementations of a simple, cheap, index-following mandate.

• THNR Casts wider than the drugmakers: the mandate covers telehealth providers and other firms tied to rising use of weight-loss treatments.amplifyetfs.com
• Rules-based, not a hunch. It tracks VettaFi's Weight Loss Drug & Treatment Index (THINR), so the lineup changes by published methodology.
• Global by design, so European drugmakers count as much as US ones. Launched in 2024, as GLP-1 treatments moved from niche to headline.

Worth knowing

• IHE Cap weighting across about 60 names puts the largest US drug makers in the driver's seat; XPH uses modified equal weight to spread dollars across large, mid and small caps.ssga.com
• Pharma only. No biotech, devices or insurers, and the fund is non-diversified, making it a narrow slice of health care.ishares.com
• The 0.37% fee undercuts the category median but not the floor: XPH at 0.35% and PPH at 0.36% shade it slightly.

• THNR The 0.59% expense ratio runs a touch above what global thematic funds typically charge.
• A small fund that trades lightly, so spreads can be wider than on big index funds. Limit orders are the usual tool here.
• One storyline, one drug class. Concentrated by construction, and distributions land annually or semiannually rather than as steady income.

Full IHE profile⁠

Full THNR profile⁠